Roles of Post-Translational Modifications of Transcription Factors Involved in Breast Cancer Hypoxia

Overview

Journal Molecules

Publisher MDPI

Specialty Biology

Date 2025 Feb 13

PMID 39942749

Authors

Logan Seymour

Niyogushima Nuru

Kaya R Johnson

Jennifer Michel Villalpando Gutierrez

Victor Tochukwu Njoku

Costel C Darie

Anca-Narcisa Neagu

Affiliations

Soon will be listed here.

Abstract

BC is the most commonly diagnosed cancer and the second leading cause of cancer death among women worldwide. Cellular stress is a condition that leads to disrupted homeostasis by extrinsic and intrinsic factors. Among other stressors, hypoxia is a driving force for breast cancer (BC) progression and a general hallmark of solid tumors. Thus, intratumoral hypoxia is an important determinant of invasion, metastasis, treatment failure, prognosis, and patient mortality. Acquisition of the epithelial-mesenchymal transition (EMT) phenotype is also a consequence of tumor hypoxia. The cellular response to hypoxia is mainly regulated by the hypoxia signaling pathway, governed by hypoxia-inducible factors (HIFs), mainly HIF1α. HIFs are a family of transcription factors (TFs), which induce the expression of target genes involved in cell survival and proliferation, metabolic reprogramming, angiogenesis, resisting apoptosis, invasion, and metastasis. HIF1α cooperates with a large number of other TFs. In this review, we focused on the crosstalk and cooperation between HIF1α and other TFs involved in the cellular response to hypoxia in BC. We identified a cluster of TFs, proposed as the HIF1α-TF interactome, that orchestrates the transcription of target genes involved in hypoxia, due to their post-translational modifications (PTMs), including phosphorylation/dephosphorylation, ubiquitination/deubiquitination, SUMOylation, hydroxylation, acetylation, S-nitrosylation, and palmitoylation. PTMs of these HIF1α-related TFs drive their stability and activity, degradation and turnover, and the bidirectional translocation between the cytoplasm or plasma membrane and nucleus of BC cells, as well as the transcription/activation of proteins encoded by oncogenes or inactivation of tumor suppressor target genes. Consequently, PTMs of TFs in the HIF1α interactome are crucial regulatory mechanisms that drive the cellular response to oxygen deprivation in BC cells.

References

Liu J, Zhang C, Zhao Y, Yue X, Wu H, Huang S . Parkin targets HIF-1α for ubiquitination and degradation to inhibit breast tumor progression. Nat Commun. 2017; 8(1):1823. PMC: 5703960. DOI: 10.1038/s41467-017-01947-w. View

Tecalco-Cruz A, Ramirez-Jarquin J, Cruz-Ramos E . Estrogen Receptor Alpha and its Ubiquitination in Breast Cancer Cells. Curr Drug Targets. 2018; 20(6):690-704. DOI: 10.2174/1389450119666181015114041. View

Li Z, Wei H, Li S, Wu P, Mao X . The Role of Progesterone Receptors in Breast Cancer. Drug Des Devel Ther. 2022; 16:305-314. PMC: 8801368. DOI: 10.2147/DDDT.S336643. View

Ooshima A, Park J, Kim S . Phosphorylation status at Smad3 linker region modulates transforming growth factor-β-induced epithelial-mesenchymal transition and cancer progression. Cancer Sci. 2018; 110(2):481-488. PMC: 6361575. DOI: 10.1111/cas.13922. View

Paltoglou S, Roberts B . HIF-1alpha and EPAS ubiquitination mediated by the VHL tumour suppressor involves flexibility in the ubiquitination mechanism, similar to other RING E3 ligases. Oncogene. 2006; 26(4):604-9. DOI: 10.1038/sj.onc.1209818. View

Ma J, Qin L, Li X . Role of STAT3 signaling pathway in breast cancer. Cell Commun Signal. 2020; 18(1):33. PMC: 7048131. DOI: 10.1186/s12964-020-0527-z. View

Montagner M, Enzo E, Forcato M, Zanconato F, Parenti A, Rampazzo E . SHARP1 suppresses breast cancer metastasis by promoting degradation of hypoxia-inducible factors. Nature. 2012; 487(7407):380-4. DOI: 10.1038/nature11207. View

Desvergne B, Michalik L, Wahli W . Transcriptional regulation of metabolism. Physiol Rev. 2006; 86(2):465-514. DOI: 10.1152/physrev.00025.2005. View

Zhong Q, Xiao X, Qiu Y, Xu Z, Chen C, Chong B . Protein posttranslational modifications in health and diseases: Functions, regulatory mechanisms, and therapeutic implications. MedComm (2020). 2023; 4(3):e261. PMC: 10152985. DOI: 10.1002/mco2.261. View

10.

Anderson A, Ragan M . Palmitoylation: a protein -acylation with implications for breast cancer. NPJ Breast Cancer. 2017; 2():16028. PMC: 5515344. DOI: 10.1038/npjbcancer.2016.28. View

11.

Wang R, Zhang P, Li J, Guan H, Shi G . Ubiquitination is absolutely required for the degradation of hypoxia-inducible factor--1 alpha protein in hypoxic conditions. Biochem Biophys Res Commun. 2016; 470(1):117-122. DOI: 10.1016/j.bbrc.2016.01.005. View

12.

Gao Y, Wang R, Liu J, Zhao K, Qian X, He X . SENP1 promotes triple-negative breast cancer invasion and metastasis via enhancing CSN5 transcription mediated by GATA1 deSUMOylation. Int J Biol Sci. 2022; 18(5):2186-2201. PMC: 8935229. DOI: 10.7150/ijbs.60594. View

13.

Dengler V, Galbraith M, Espinosa J . Transcriptional regulation by hypoxia inducible factors. Crit Rev Biochem Mol Biol. 2013; 49(1):1-15. PMC: 4342852. DOI: 10.3109/10409238.2013.838205. View

14.

Xu W, Zhou W, Cheng M, Wang J, Liu Z, He S . Hypoxia activates Wnt/β-catenin signaling by regulating the expression of BCL9 in human hepatocellular carcinoma. Sci Rep. 2017; 7:40446. PMC: 5225427. DOI: 10.1038/srep40446. View

15.

Bakker W, Harris I, Mak T . FOXO3a is activated in response to hypoxic stress and inhibits HIF1-induced apoptosis via regulation of CITED2. Mol Cell. 2007; 28(6):941-53. DOI: 10.1016/j.molcel.2007.10.035. View

16.

Zhang T, Liu S, Durojaye O, Xiong F, Fang Z, Ullah T . Dynamic phosphorylation of FOXA1 by Aurora B guides post-mitotic gene reactivation. Cell Rep. 2024; 43(9):114739. DOI: 10.1016/j.celrep.2024.114739. View

17.

Palazon A, Goldrath A, Nizet V, Johnson R . HIF transcription factors, inflammation, and immunity. Immunity. 2014; 41(4):518-28. PMC: 4346319. DOI: 10.1016/j.immuni.2014.09.008. View

18.

Li X, Jin J, Yang S, Xu W, Meng X, Deng H . GATA3 acetylation at K119 by CBP inhibits cell migration and invasion in lung adenocarcinoma. Biochem Biophys Res Commun. 2018; 497(2):633-638. DOI: 10.1016/j.bbrc.2018.02.120. View

19.

Gao F, Li X, Xu K, Wang R, Guan X . c-MYC mediates the crosstalk between breast cancer cells and tumor microenvironment. Cell Commun Signal. 2023; 21(1):28. PMC: 9887805. DOI: 10.1186/s12964-023-01043-1. View

20.

Luond F, Sugiyama N, Bill R, Bornes L, Hager C, Tang F . Distinct contributions of partial and full EMT to breast cancer malignancy. Dev Cell. 2021; 56(23):3203-3221.e11. DOI: 10.1016/j.devcel.2021.11.006. View